Cutler Group LP Cyma Bay Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$12.63 - $24.47 $126,300 - $244,700	10,000 New	10,000 $23,000
Q2 2019 Aug 09, 2019	BUY	$6.05 - $13.66 $47,795 - $107,914	7,900 Added 464.71%	9,600 $2,000
Q1 2019 May 10, 2019	SELL	$8.16 - $13.42 $8,160 - $13,420	-1,000 Reduced 37.04%	1,700 $9,000
Q3 2018 Nov 07, 2018	SELL	$10.88 - $14.52 $27,200 - $36,300	-2,500 Reduced 48.08%	2,700 $0
Q2 2018 Aug 10, 2018	BUY	$10.66 - $14.38 $50,102 - $67,586	4,700 Added 940.0%	5,200 $5,000
Q4 2017 Jan 17, 2018	BUY	$7.67 - $9.31 $3,835 - $4,655	500	500 $1,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.